The morning after ProfoundBio
Genmab quietly reveals pipeline discontinuations and a delay to the son of Darzalex.
ESMO 2024 movers – VEGF bispecifics win, TIGIT loses
After a conference lacking the wow factor, biotech winners and losers emerge.
Macrocycle goes full Circle
A macrocycle-based therapy enters the clinic, as do projects targeting p53 interaction and IL-12.
Another vote of no-confidence in co-stimulated bispecifics
BioNTech and Genmab's acasunlimab is the latest 4-1BB project to stumble.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
